Article
A new genetic defect in human CYP2C19: mutation of the initiation codon is responsible for poor metabolism of S-mephenytoin.
The Journal of pharmacology and experimental therapeutics - 1 Jan 1998
Ferguson R J, De Morais S M, Benhamou S, Bouchardy C, Blaisdell J, Ibeanu G, Wilkinson G R, Sarich T C, Wright J M, Dayer P, Goldstein J A
Abstract excerpt
The 4'-hydroxylation of the S-enantiomer of the anticonvulsant drug mephenytoin exhibits a genetic polymorphism in humans. This polymorphism shows marked interracial heterogeneity, with the poor metabolizer (PM) phenotype representing 2 to 5% of Caucasian and 13 to 23% of Asian populations. Two defective CYP2C19 alleles, CYP2C19*2 and CYP2C19*3, have been described which account for approximately 87% of Caucasian...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.